{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-059570","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2021-12-07T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.745146+00:00","generated_at":"2026-06-28T03:12:22.187958+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"AbCellera appoints Andrew Lo as independent director; John Hamer resigns","bullets":["Andrew W. Lo, Ph.D., appointed as independent director effective December 7, 2021.","Lo will serve on Audit and Compensation Committees; he is an MIT professor and TIME 100 honoree.","John Hamer, Ph.D., managing partner at DCVC Bio, resigned from the board effective immediately.","Hamer had served on the board since 2018, including on Audit and Compensation Committees.","CEO Carl Hansen thanked Hamer for his guidance and welcomed Lo for his financial/biomedical expertise."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-059570","json":"https://secwatch.observer/filing/0001564590-21-059570.json","markdown":"https://secwatch.observer/filing/0001564590-21-059570.md","text":"https://secwatch.observer/filing/0001564590-21-059570.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000156459021059570/0001564590-21-059570-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000156459021059570/abcl-8k_20211207.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T03:12:22.187958+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}